ArticleRevista medica del Instituto Mexicano del Seguro Social2024
[Immunoglobulin G4 disease with pancreatic affectation: the mimicker of malignancy].
Article in Revista medica del Instituto Mexicano del Seguro Social, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: mmunoglobulin G subclass 4-related disease (IgG4-RD) is characterized by elevated serum IgG4 levels and tissue infiltration by IgG4-positive plasma cells. It has a varied clinical presentation, and definitive diagnosis requires rigorous clinicopathological correlation. Clinical case: 47-year-old male patient with a history of weight loss of 35 kg over 2 years, accompanied by the presence of pulmonary nodules and alterations in pancreatic morphology detected by imaging, which was assessed as a probable pancreatic neoplasm; however, IgG4-RD was suspected during the approach, which is why serum IgG4 levels and a biopsy of the submandibular gland were requested, fulfilling the diagnostic criteria, consequently starting treatment with rituximab with an adequate response. Conclusion: IgG4-RD is a rare disease that many times is not considered as a differential diagnosis, leading to diagnostic delays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.